Recent progress in the use of glucagon and glucagon receptor antagonists in the treatment of diabetes mellitus

Open Medicinal Chemistry Journal

Volumn 8, Issue , 2014, Pages 28-35

  Lotfy, Mohamed ^a,b,c   Kalasz, Huba ^d   Szalai, Gyorgy ^e   Singh, Jaipaul ^f   Adeghate, Ernest ^g  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e ST JOHN'S HOSPITAL   (Hungary)

^f UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^g UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Diabetes mellitus; Glucagon; Glucagon receptor antagonists; Pancreas

Indexed keywords

5 HYDROXYALKYL 4 PHENYLPYRIDINE; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BI 32169; BICYCLIC 19 RESIDUE PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON RECEPTOR; GLUCAGON RECEPTOR ANTAGONIST; ISOSERINE; MONOCLONAL ANTIBODY; N [3 CANO 6 (1,1 DIMETHYLPROPYL) 4,5,6,7 TETRAHYDRO 1 BENZOTHIEN 2 YL] 2 ETHYLBUTAMIDE; NEUTRALIZING ANTIBODY; NNC 250926; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; EPIGENETICS; GLUCAGON BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; KNOCKOUT GENE; LIPID METABOLISM; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 84928989530     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501408010028     Document Type: Article

References (69)

1. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterol., 2007, 132, 2131-57.
2. Duffy, J.L.; Kirk, B.A.; Konteatis, Z.; Campbell, E.L.; Liang, R.; Brady, E.J.; Candelore, M.R.; Ding, V.D.; Jiang, G.; Liu, F.; Qure-shi, S.A.; Saperstein, R.; Szalkowski, D; Tong, S.; Tota, L.M.; Xie, D; Yang, X.; Zafian, P.; Zheng, S.; Chapman, K.T.; Zhang, B.B.; Tata, J.R. Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor. Bioorg. Med. Chem. Lett., 2005, 15, 1401-05.
3. Al-Shamsi, M.; Amin, A.; Adeghate, E. Vitamin E decreases the hyperglucagonemia of diabetic rats. Ann. NY Acad. Sci., 2006, 1084, 432-41.
4. Ponery, A.S.; Adeghate, E. Distribution of NPY and SP and their effects on glucagon secretion from the in vitro normal and diabetic pancreatic tissues. Peptides, 2000, 21(10), 1503-09.
5. Quesada, I.; Tuduri, E.; Ripoll, C.; Nadal, A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose ho-meostasis and diabetes. J. Endocrinol., 2008, 199, 5-19.
6. Xu, E.; Kumar, M.; Zhang, Y.; Ju, W.; Obata, T.; Zhang, N.; Liu, S.; Wendt, A.; Deng, S.; Ebina, Y.; Wheeler, M.B.; Braun, M.; Wang, Q. Intra-islet insulin suppresses glucagon release via GABA-GABA(A) receptor system. Cell Metab. 2006, 3, 47-8.
7. Pierce, K.L.; Premont, R.T.; Lefkowitz, R.J. Seven transmembrane receptors. Nat. Rev. Mol. Cell Biol., 2002, 3, 639-50.
8. Lok, S.; Kuijper, J.L.; Jelinek, L.J.; Kramer, J.M.; Whitmore, T.E.; Sprecher, C.A.; Mathewes, S.; Grant, F.J.; Biggs, S.H.; Rosenberg, G.B. The human glucagon receptor-encoding gene: structure, cDNA sequence and chromosomal localization. Gene, 1994, 140(2), 203-09.
9. Shah, P.; Vella, A.; Basu, A.; Basu, R.; Schwenk, W.F.; Rizza, R.A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab., 2000, 85, 4053-59.
10. McGarry, J.D.; Foster, D.W. Regulation of hepatic fatty acid oxidation and ketone body production. Annu. Rev. Biochem., 1980, 49, 395-20.
11. Hansen, L.H.; Abrahamsen, N.; Nishimura, E. Glucagon receptor mRNA distribution in rat tissues. Peptides, 1995, 16, 1163-66.
12. Burcelin, R.; Katz, E.B.; Charron, M.J. Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Diabetes Metab., 1996, 22, 373-96.
13. Birnbaumer, L.; Pohl, S.L.; Rodbell, M. The glucagon-sensitive adenylate cyclase system in plasma membranes of rat liver. VII. Hormonal stimulation: reversibility and dependence on concentration of free hormone. J. Biol. Chem., 1972, 247, 2038-43.
14. Shah, P.; Basu, A.; Basu, R.; Rizza, R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am. J. Physiol. Endocrinol. Metab., 1999, 277, E283-90.
15. Jiang, G.; Zhang, B.B. Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab., 2003, 284, E671-78.
16. Gelling, R.W.; Du, X.Q.; Dichmann, D.S.; Romer, J.; Huang, H.; Cui, L.; Obici, S.; Tang, B.; Holst, J.J.; Fledelius, C.; Johansen, P.B.; Rossetti, L.; Jelicks, L.A.; Serup, P.; Nishimura, E.; Charron, M.J. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. USA, 2003, 100, 1438-43.
17. Zhang, B.B.; Moller, D.E. New approaches in the treatment of type 2 diabetes. Curr. Opin. Chem. Biol., 2000, 4, 461-67.
18. Conarello, S.L.; Jiang, G.; Mu, J.; Li, Z.; Woods, J.; Zycband, E.; Ronan, J.; Liu, F.; Roy, R.S.; Zhu, L.; Charron, M.J.; Zhang, B.B. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia, 2007, 50, 142-50.
19. Lee, Y.; Wang, M-Y.; Du, X.Q.; Charron, M.J.; Unger, R.H. Glu-cagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice. Diabetes, 2011, 60, 391-97.
20. Parker, J.C.; Andrews, K.M.; Allen, M.R.; Stock, J.L.; Mc-Neish, J.D. Glycemic control in mice with targeted disruption of the glu-cagon receptor gene. Biochem. Biophys. Res. Commun., 2002, 290, 839-43.
21. Longuet, C.; Sinclair, E.M.; Maida, A.; Baggio, L.L.; Maziarz, M.; Charron, M.J.; Drucker, D.J. The Glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab., 2008, 8, 359-71.
22. Sorensen, H.; Brand, C.L.; Neschen, S.; Holst, J.J.; Fosgerau, K.; Nishimura, E.; Shulman, G.I. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes, 2006, 55, 2843-48.
23. Cho, Y.M.; Merchant, C.E.; Kieffer, T.J. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol. Ther., 2012, 135(3), 247-78.
24. Liang, Y.; Osborne, M.C.; Monia, B.P.; Bhanot, S.; Gaarde, W.A.; Reed, C.; She, P.; Jetton, T.L.; Demarest, K.T. Reduction in gluca-gon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes, 2004, 53, 410-17.
25. Sloop, K.W.; Cao, J.X.; Siesky, A.M.; Zhang, H.Y.; Bodenmiller, D.M.; Cox, A.L.; Jacobs, S.J.; Moyers, J.S.; Owens, R.A.; Showal-ter, A.D.; Brenner, M.B.; Raap, A.; Gromada, J.; Berridge, B.R.; Monteith, D.K.; Porksen, N.; McKay, R.A.; Monia, B.P.; Bhanot, S.; Watts, L.M.; Michael, M.D. Hepatic and glucagonlike peptide-1-mediated reversal of diabetes by glucagon receptor antisense oli-gonucleotide inhibitors. J. Clin. Invest., 2004, 113, 1571-81.
26. Ali, S.; Drucker, D.J. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am. J. Physiol. Endo-crinol. Metab., 2009, 296, E415-21.
27. Brand, C.L.; Rolin, B.; Jørgensen, P.N.; Svendsen, I.; Kristensen, J.S.; Holst, J.J. Immunoneutralisation of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia, 1994, 37, 985-93.
28. Brand, C.L.; Jørgensen, P.N.; Knigge, U.; Warberg, J.; Svendsen, I.; Kristensen, J.S.; Holst, J.J. Role of glucagon in maintanence of euglycemia in fed and fasted rats. Am. J. Physiol., 1995, 32, E469-77.
29. Brand, C.L.; Joergensen, P.N.; Svendsen, I.; Holst, J.J. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes, 1996, 45, 1076-83.
30. Brand, C.L.; Hansen, B.; Gronemann, S.; Moysen, M.; Holst, J.J. Subchronic glucagon neutralisation improves diabetes in ob/ob mice. Diabetes, 2000, 49(S1), A81.
31. Ling, A.; Hong, Y.; Gonzalez, J.; Gregor, V.; Polinsky, A.; Kuki, A.; Shi, S.; Teston, K.; Murphy, D.; Porter, J.; Kiel, D.; Lakis, J.; Anderes, K.; May, J.; Knudsen, L.B.; Lau, J. Identification of alky-lidene hydrazides as glucagon receptor antagonists. J. Med. Chem., 2001, 44, 3141-49.
32. Ling, A.; Plewe, M.; Gonzalez, J.; Madsen, P.; Sams, C.K.; Lau, J.; Gregor, V.; Murphy, D.; Teston, K.; Kuki, A.; Shi, S.; Truesdale, L.; Kiel, D.; May, J.; Lakis, J.; Anderes, K.; Iatsimirskaia, E.; Sidelmann, U.G.; Knudsen, L.B.; Brand, C.L.; Polinsky, A. Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg. Med. Chem., 2002, 12, 663-66.
33. Cascieri, M.A.; Koch, G.E.; Ber, E.; Sadowski, S.J.; Louizides, D.; de Laszlo, S.E.; Hacker, C.; Hagmann, W.K.; MacCoss, M.; Chic-chi, G.G.; Vicario, P.P. Characterization of a novel, nonpeptidyl antagonist of the human glucagon receptor. J. Biol. Chem., 1999, 274, 8694-97.
34. Shiao, L.L.; Cascieri, M.A.; Trumbauer, M.; Chen, H.; Sullivan, K.A. Generation of mice expressing the human glucagon receptor with a direct replacement vector. Transgenic Res., 1999, 8, 295-02.
35. Dharanipragada, R.; Trivedi, D.; Bannister, A.; Siegel, M.; Tourwe, D.; Mollova, N.; Schram, K.; Hruby, V.J. Synthetic linear and cyclic glucagon antagonists. Int. J. Pept. Protein Res., 1993, 42, 68-7.
36. Hruby, V.J. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs. Mol. Cell Biochem., 1982, 44, 49-64.
37. Hruby, V.J.; Gysin, B.; Trivedi, D.; Johnson, D.G. New glucagon analogues with conformational restrictions and altered amphiphilic-ity: effects on binding, adenylate cyclase and glycogenolytic activities. Life Sci., 1993, 52, 845-55.
38. Dallas-Yang, Q.; Shen, X.; Strowski, M.; Brady, E.; Saperstein, R.; Gibson, R.E.; Szalkowski, D.; Qureshi, S.A.; Candelore, M.R.; Fenyk-Melody, J.E.; Parmee, E.R.; Zhang, B.B.; Jiang, G. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur. J. Pharmacol., 2004, 501, 225-34.
39. Johnson, D.G.; Goebel, C.U.; Hruby, V.J.; Bregman, M.D.; Trivedi, D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science, 1982, 215, 1115-6.
40. Unson, C.G.; Gurzenda, E.M.; Merrifield, R.B. Biological activities of des His1[Glu9]glucagon amide, a glucagon antagonist. Peptides, 1989, 10, 1171-7.
41. Ahn, J.M.; Medeiros, M.; Trivedi, D.; Hruby, V.J. Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4. J. Pept. Res., 2001, 58(2), 151-8.
42. Potterat, O.; Wagner, K.; Gemmecker, G.; Mack, J.; Puder, C.; Vettermann, R.; Streicher, R. BI-32169, a Bicyclic 19-Peptide with Strong Glucagon Receptor Antagonist Activity from Streptomyces sp. J. Nat. Prod., 2004, 67(9), 1528-31.
43. Knappe, T.A.; Linne, U.; Xie, X.; Marahiel, M.A. The glucagon receptor antagonist BI-32169 constitutes a new class of lasso pep-tides. FEBS Lett., 2010, 584, 785-9.
44. Merlen, C.; Fabrega, S.; Desbuquois, B.; Unson, C.G.; Authier, F. Glucagon-mediated internalization of serine-phosphorylated gluca-gon receptor and Gsa in rat liver. FEBS Lett., 2006, 580, 5697-04.
45. Van Tine, B.A.; Azizeh, B.Y.; Trivedi, D.; Phelps, J.R.; Houslay, M.D.; Johnson, D.G.; Hruby, V.J. Low level cyclic adenosine 3', 5'-monophosphate accumulation analysis of [des-His1, des-Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinol., 1996, 137, 3316-22.
46. Kodra, J.T.; Jørgensen, A.S.; Andersen, B.; Behrens, C.; Brand, C.L.; Christensen, I.T.; Guldbrandt, M.; Jeppesen, C.B.; Knudsen, L.B.; Madsen, P.; Nishimura, E.; Sams, C.; Sidelmann, U.G.; Pedersen, R.A.; Lynn, F.C.; Lau, J. Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent in-sulinotropic polypeptide receptor. J. Med. Chem., 2008, 51(17), 5387-96.
47. Rivera, N.; Everett-Grueter, C.A.; Edgerton, D.S.; Rodewald, T.; Neal, D.W.; Nishimura, E.; Larsen, M.O.; Jacobsen, L.O.; Kris-tensen, K.; Brand, C.L.; Cherrington, A.D. A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog. J. Pharmacol. Exp. Ther., 2007, 321(2), 743-52.
48. Petersen, K.F.; Sullivan, J.T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia, 2001, 44, 2018-24.
49. Ladouceur, G.H.; Cook, J.H.; Doherty, E.M.; Schoen, W.R.; Mac-Dougall, M.L.; Livingston, J.N. Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists. Bioorg. Med. Chem. Lett., 2002, 12, 461-4.
50. Qureshi, S.A.; Candelore, M.R.; Xie, D.; Yang, X.; Tota, L.M.; Ding, VD-H.; Li, Z.; Bansal, A.; Miller, C.; Cohen, S.M.; Jiang, G.; Brady, E.; Saperstein, R.; Duffy, J.L.; Tata, J.R.; Chapman, K.T.; Moller, D.E.; Zhang, B.B. A Novel Glucagon Receptor Antagonist Inhibits Glucagon Mediated Biological Effects. Diabetes, 2004, 53, 3267-73.
51. Parker, J.C.; McPherson, R.K.; Andrews, K.M.; Levy, C.B.; Dubins, J.S.; Chin, J.E.; Perry, P.V.; Hulin, B.; Perry, D.A.; Ina-gaki, T.; Dekker, K.A.; Tachikawa, K.; Sugie, Y.; Treadway, J.L. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes, 2000, 49, 2079-86.
52. Kurukulasuriya, R.; Sorensen, B.K.; Link, J.T., Patel, J.R.; Jae, H.S.; Winn, M.X.; Rohde, J.R.; Grihalde, N.D.; Lin, C.W.; Ogiela, C.A.; Adler, A.L.; Collins, C.A. Biaryl amide glucagon receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14(9), 2047-50.
53. Shen, D.M.; Zhang, F.; Brady, E.J.; Candelore, M.R.; Dallas-Yang, Q.; Ding, V.D.; Dragovic, J.; Feeney, W.P.; Jiang, G.; McCann, P.E.; Mock, S.; Qureshi, S.A.; Saperstein, R.; Shen, X.; Tam-vakopoulos, C.; Tong, X.; Tota, L.M.; Wright, M.J.; Yang, X.; Zheng, S.; Chapman, K.T.; Zhang, B.B.; Tata, J.R.; Parmee, E.R. Discovery of novel, potent, and orally active spiro-urea human glu-cagon receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15(20), 4564-69.
54. Liang, R.; Abrardo, L.; Brady, E.J.; Candelore, M.R.; Ding, V.; Saperstein, R.; Tota, L.M.; Wright, M.; Mock, S.; Tamvakopolous, C.; Tong, S.; Zheng, S.; Zhang, B.B.; Tata, J.R.; Parmee, E.R. Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor. Bioorg. Med. Chem. Lett., 2007, 17(3), 587-92.
55. Shen, D.M.; Brady, E.J.; Candelore, M.R.; Dallas-Yang, Q.; Ding, V.D.; Feeney, W.P.; Jiang, G.; McCann, M.E.; Mock, S.; Qureshi, S.A.; Saperstein, R.; Shen, X.; Tong, X.; Tota, L.M.; Wright, M.J.; Yang, X.; Zheng, S.; Chapman, K.T.; Zhang, B.B.; Tata, J.R.; Par-Mee, E.R. Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core. Bioorg. Med. Chem. Lett., 2011, 21(1), 76-81.
56. Kim, R.M.; Chang, J.; Lins, A.R.; Brady, E.; Candelore, M.R.; Dallas-Yang, Q.; Ding, V.; Dragovic, J.; Iliff, S.; Jiang, G.; Mock, S.; Qureshi, S.; Saperstein, R.; Szalkowski, D.; Tamvakopoulos, C.; Tota, L.; Wright, M.; Yang, X.; Tata, J.R.; Chapman, K.; Zhang, B.B.; Parmee, E.R. Discovery of potent, orally active ben-zimidazole glucagon receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18(13), 3701-05.
57. Lau, J.; Behrens, C.; Sidelmann, U.G.; Knudsen, L.B.; Lundt, B.; Sams, C.; Ynddal, L.; Brand, C.L.; Pridal, L.; Ling, A.; Kiel, D.; Plewe, M.; Shi, S.; Madsen, P. New beta-alanine derivatives are orally available glucagon receptor antagonists. J. Med. Chem., 2007, 50(1), 113-28.
58. Hamm, C.A.; Costa, F.F. The impact of epigenomics on future drug design and new therapies. Drug Discov Today, 2011, 16(13), 626-35.
59. Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; Lee, L.; Ye, Z.; Ngo, Q-M.; Edsall, L.; Antosiewicz-Bourget, J.; Stewart, R.; Ruotti, V.; Millar, A.H.; Thomson, J.A.; Ren, B.; Ecker, J.R. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature, 2009, 462(7271), 315-22.
60. Ray-Gallet, D.; Almouzni, G. Nucleosome dynamics and histone variants. Essays Biochem., 2010, 48, 75-87.
61. Costa, F.F. Non-coding RNAs, epigenetics and complexity. Gene, 2008, 410, 9-17.
62. Pogribny, I.P.; Beland, F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol. Life Sci., 2009, 66, 2249-61.
63. Wang, Q.; Li, L.; Xu, E.; Wong, V.; Rhodes, C; Brubaker, P.L. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Dia-betologia, 2004, 47(3), 478-87.
64. Pinney, S.E.; Simmons, R.A. Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol. Metab., 2010, 21, 223-9.
65. Evans-Molina, C; Robbins, R.D.; Kono, T.; Tersey, S.A.; Vester-mark, G.L.; Nunemaker, C.S.; Garmey J.C.; Deering T.G.; Keller S.R.; Maier B.; Mirmira, R.G. Peroxisome proliferator-activated receptor y activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of eu-chromatin structure. Mol. Cell Biol, 2009, 29(8), 2053-67.
66. Christensen, D.P.; Dahllöf, M.; Lundh, M.; Rasmussen, D.N.; Nielsen, M.D.; Billestrup, N.; Grunnet, L.G.; Mandrup-Poulsen, T. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med., 2011, 17(5-6), 378.
67. Soupart, A.; Coffernils, M.; Couturier, B.; Gankam-Kengne, F.; Decaux, G. (2012). Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin. J. Am. Soc. Nephrol, 2012, 7(5), 742-7.
68. Sinz, C; Chang, J.; Lins, A. R.; Brady, E.; Candelore, M.; Dallas-Yang, Q.; Ding, V.; Jiang, G.; Lin, Z.; Mock, S.; Qureshi, S.; Salituro, G.; Saperstein, R.; Shang, J.; Szalkowski, D.; Tota, L.; Vincent, S.; Wright, M.; Xu, S.; Yang, X.; Zhang, B.; Tata, J.; Kim, R.; Parmee, E. (2011). Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists. Bioorg Med. Chem. Lett, 2011, 21(23), 7131-6.
69. Kawai, K.; Kato, T.; Mori, H.; Kitamura, J.; Nozawa, Y. A comparative study on cytotoxicities and biochemical properties of an-thraquinone mycotoxins emodin and skyrin from Penicillium is-landicum Sopp. Toxicol. Lett, 1984, 20(2),155-60.